NICE's Andrew Dillon says Kadcyla is too expensive for use on the NHS but Roche's Jennifer Cozzone says it has already been picked up elsewhere. Report by Fudgea. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
